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Abstract  
Background One useful application of pattern matching algorithms is identification of major histocom-
patability complex (MHC) ligands and T-cell epitopes. Peptides that bind to MHC molecules and interact 
with T cell receptors to stimulate the immune system are critical antigens for protection against infectious 
pathogens. We describe a genomes-to-vaccine approach to H. pylori vaccine design that takes advantage 
of immunoinformatics algorithms to rapidly identify T-cell epitope sequences from large genomic datasets. 
Results To design a globally relevant vaccine, we used computational methods to identify a core genome 
comprised of 676 open reading frames (ORFs) from amongst seven genetically and phenotypically diverse 
H. pylori strains from around the world. Of the 1,241,153 9-mer sequences encoded by these ORFs, 
106,791 were identical amongst all seven genomes and 23,654 scored in the top 5% of predicted HLA 
ligands for at least one of eight archetypal Class II HLA alleles when evaluated by EpiMatrix. To maximize 
the number of epitopes that can be assessed experimentally, we used a computational algorithm to in-
crease epitope density in 20-25 amino acid stretches by assembling potentially immunogenic 9-mers to be 
identically positioned as they are in the native protein antigen. 1,805 immunogenic consensus sequences 
(ICS) were generated. 79% of selected ICS epitopes bound to a panel of 6 HLA Class II haplotypes, repre-
senting >90% of the global human population.  
Conclusions  The breadth of H. pylori genome datasets was computationally assessed to rapidly and care-
fully determine a core set of genes. Application of immunoinformatics tools to this gene set accurately pre-
dicted epitopes with promising properties for T cell-based vaccine development.  
Background  
A genomes-to-vaccine strategy for rational vaccine 
design rests on the premises that (i) a minimal set of 
immunogens capable of inducing a robust and sus-
tained immune response to a pathogen can be dis-
covered using immunoinformatics, and (ii) admini-
stration of these immunogens, in a suitable delivery 
vehicle together with adjuvant, will result in       
protection from disease. Our approach is to identify 
the minimal, essential information needed to 
achieve this goal. That data is encoded, in part, by T
-cell epitopes, short peptide sequences displayed by 
antigen presenting cells to T cells, critical mediators 
of adaptive immunity. Four major steps comprise 
our genomes-to-vaccine strategy, which can be 
thought of as a funnelling process (Figure 1): (i) 
Genomes are mined using computational tools to 
identify genes that encode proteins with promising 
vaccine antigen properties such as secretion, up-
regulated expression, immunogenicity and viru-
lence; (ii) immunoinformatics tools are then used to 
map protein sequences for short, linear putative T-
cell epitopes; (iii) sequences are synthesized as pep-
tides and evaluated for human leukocyte antigen 
(HLA) binding and antigenicity in survivors of in-
fection or vaccinees and (iv) prototype epitope-
based vaccines are evaluated for immunogenicity 
and efficacy in humanized mice. We adopted this 
genomes-to-vaccine strategy to design a vaccine 
against Helicobacter pylori (H. pylori), a motile, 
gram-negative spiral bacterium that colonizes gas-
tric mucosa. Approximately one-half of the world‟s 
population is infected with H. pylori, and the infec-
tion persists for life unless treated with combination 
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antimicrobials. Natural immune response does not 
eliminate infection nor does it confer protective im-
munity against re-infection after antimicrobial ther-
apy. Chronic infection may lead to development of 
chronic     gastritis, peptic ulceration, and even gas-
tric adenocarcinoma and lymphoma; hence the need 
for a protective vaccine [1]. 
 
Here, we set out to characterize the human T cell 
response to H. pylori infection using an informatics-
driven epitope mapping approach. H. pylori im-
munopathogenesis has been thoroughly character-
ized, providing important insights into how this bac-
terial pathogen interfaces with the host immune sys-
tem and evades host defenses, allowing it to persist 
in the gastric environment [2]. How H. pylori man-
ages to trigger epitope-specific immune responses at 
the molecular level is not yet well-understood and 
requires further investigation in order to develop 
prophylactic and therapeutic vaccines. The avail-
ability of sequenced H. pylori genomes and immu-
noinformatics tools capable of their analysis enables 
experimental analysis of sequences that directly 
stimulate and inhibit multi-functional human T cell 
responses.  An example of the use of this genomic 
sequence data would be to predict how T cells will 
respond to stimulation by H. pylori sequences that 
have homologues in the human genome and the hu-
man gut microbiome in order to understand the im-
pact of H. pylori infection on autologous and het-
erologous immunity. This information is especially 
valuable to rational vaccine design because vaccines 
should not contain cross-reactive epitopes that can 
break self-tolerance and lead to autoimmune dis-
ease. 
In preliminary studies, we computationally identi-
fied T-cell epitopes from the H. pylori J99 and 
26695 genomes that stimulated long-lived immune 
responses and cleared infection in a p27 knockout 
mouse model of H. pylori infection [3,4]. Here, in 
the first phase of a more expansive and translational 
study, we computationally screened seven H. pylori 
genomes to identify T-cell epitopes that may serve 
as human vaccine immunogens. This involved mul-
tiple steps in a funnelling process that progressively 
narrowed down the search universe to yield a set of 
sequences for experimental evaluation: (i) Open 
reading frame (ORF) amino acid sequences were 
compared across genomes to identify conserved 
proteins. (ii) 9-mer sequences completely conserved 
across all genomes in this protein subset were iden-
tified using the Conservatrix algorithm. (iii) Among 
these sequences, potential HLA binders were pre-
dicted using the EpiMatrix epitope mapping algo-
rithm. (iv) Immunogenic consensus sequences (ICS) 
were constructed using EpiAssembler. (v) Se-
quences bearing homology to human sequences 
were triaged. (vi) Finally, ICS were selected for ex-
perimental validation and (vii) assayed for binding 
to multiple HLA alleles. 
 
Results and Discussion  
H. pylori genomes 
We assembled the seven H. pylori genomes avail-
able in the public domain as of September 2009 in 
order to represent, as widely as possible, the breadth 
of genetic diversity of H. pylori strains available at 
the time of our computational analysis. Because 
different bacterial genotypes with a broad range of 
chronic inflammatory sequelae predominate in dif-
ferent human populations, vaccination with immu-
nogens common to these strains may provide effec-
tive protection worldwide.  
The 26695 strain of H. pylori was derived from a 
gastritis patient in the United Kingdom. Prior to 
sequencing, it underwent repeated subculturing. The 
26695 genome was the first to be sequenced and has 
since been the most thoroughly H. pylori genome 
characterized [5]. Therefore, 26695 served as the 
reference genome for comparison to the other six in 
our study. 
H. pylori strain J99 was isolated from a patient with 
duodenal ulcer disease in the USA in 1994 [6]. It 
underwent little subculturing prior to sequencing. 
The B128 strain was isolated from a patient with 
gastric ulcer disease, while 98-10, which is most 
closely related to H. pylori strains of East Asian 
Figure 1 - Genomes-to-
Vaccine Strategy. 
Genomes are mined using 
computational and experimen-
tal tools to identify genes that 
encode proteins with promis-
ing vaccine antigen properties 
such as secretion, up-
regulated expression and 
virulence. In silico. Immu-
noinformatics tools are then 
used to map protein sequences 
for short, linear putative T cell 
epitopes. In vitro. Candidates 
are synthesized as peptides 
and evaluated for MHC bind-
ing and antigenicity. In vivo. 
Prototype epitope-based 
vaccines are evaluated for 
immunogenicity and protec-
tion in humanized mice. Used 
with kind permission from 
Medicine and Health Rhode 
Island [25]. 
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origin, was isolated from a gastric cancer patient in 
Japan [7]. The HPAG1 strain was isolated from a 
Swedish patient with chronic atrophic gastritis, an 
inflammatory condition of the gastric mucosa, 
which is a precursor to lesion development and gas-
tric adenocarcinoma [8]. Shi470 was cultured from 
the gastric antrum of an Amerindian resident of a 
remote Amazonian village in Shimaa, Peru [9]. This 
strain is more closely related to strains from East 
Asia than other geographic regions, and is thought 
to represent the strains of Native Americans prior to 
European conquest. It represents the first com-
pletely sequenced strain that is not from an ethnic 
European. The G27 strain is a laboratory strain ex-
tensively used in H. pylori research, originally iso-
lated from the stomach of an Italian patient [10]. 
Thus, the genomes selected for this analysis repre-
sent geographically diverse isolates, of both labora-
tory and clinical origin, and are representative of the 
varied clinical outcome of H. pylori infection. 
  
Core genome determination 
We set out to discover vaccine immunogens com-
mon to the seven H. pylori strains in order to design 
a vaccine that will broadly cover H. pylori strains 
worldwide. To do this, we first identified the H. py-
lori core genome in a two-phased process involving 
comparative amino acid frequency followed by se-
quence similarity analyses. For every ORF in the 
reference strain (26695), ORFs in each of the other 
strains were screened for relatedness by amino acid 
composition. While composition is not as precise a 
measure of relatedness as sequence identity, the in-
formation it offers provides a rapid first-pass screen. 
We used the SΔn algorithm with a cut-off score of 
30, below which a query ORF was considered to be 
related to the reference strain ORF [11]. Related 
ORFs were then analyzed for sequence similarity by 
sequence alignment of the first 200 amino acids of 
the reference and query ORFs using the GOTOH82 
algorithm and BLOSUM50 matrix [12,13]. Analysis 
beyond the first 200 amino acids is not only compu-
tationally time intensive but also inefficient because 
it does not provide additional match-confirmation 
that could or could not be found before the 200 
amino acid cut-off. A query ORF with >80% se-
quence identity as compared with the reference 
ORF was considered a match. Matches for each ref-
erence ORF were then counted across genomes. 
Every ORF which had a match of >80% sequence 
identity in each of the 6 query genomes - represent-
ing conservation in all 7 genomes - was designated 
a member of the „core genome‟ and therefore se-
lected for downstream analysis. We found 676 
ORFs conserved across all seven genomes, repre-
senting 43% of the reference genome and corre-
sponding to a total of 4,732 ORFs out of 10,921 
ORFs in all seven genomes (Figure 2). With refer-
ence to the 26695 strain, 917, 1061, 1138, 1206 and 
1282 ORFs are found, respectively, in at least five, 
four, three, two or one of the other genomes. Of the 
1576 total ORFs in the 26695 genome, 294 (19%) 
are strain-specific (Figure 3).  
 
We note that the magnitude of the H. pylori core 
genome in the present study differs significantly 
from previously published studies. Using molecular 
biology methods or computational analyses, includ-
ing permutations of BLAST or application of 
BLAST combined with spatial analyses (e.g. 
synteny analysis), the number of ORFs comprising 
the core genome was determined to be approxi-
mately 1200 in previous studies [7,14,15,16]. As the 
total number of ORFs is close to double the 676 
reported here, we undertook a comparison of our 
dataset with select datasets representative from 
other studies to understand the discrepancy.  
The first determination of an H. pylori core genome 
was made by Salama et al. in 2000, which identified 
1281 sequences common to 15 strains using a whole 
genome microarray [14]. Five years later Gress-
mann et al. undertook a much larger sample size, 
testing 56 „representative strains‟, identified as a 
representative sample of an 800 strain unpublished 
data collection [15].  This study used microarray 
hybridization to find 1111 core genome sequences 
in a „virtual genome‟ representing 98% coverage 
Figure 2 - Informatic-Driven Reduction of Immuno-Relevant Sequence 
Space. 
Using comparative amino acid frequency and sequence similarity analyses, 
seven H. pylori genomes comprising 10,921 ORFs are reduced to a core 
subset of 4,732 ORFs. Of 1,241,153 peptides parsed, 106,791 were identi-
cal amongst all seven genomes, of which 23,654 are predicted to bind to at 
least one Class II HLA allele. These served as input into EpiAssembler, 
constructing 1,807 ICS, two of which were found to be homologous to the 
human genome by BLAST analysis.  
 Ardito et al. Immunome Research 2011, 7:2:1                
http://www.immunome-research.net/          
         Page 4 of 12 
overlap of the 26695 and J99 genomes. In 2009, 
McClain et al. identified 1237 core genes in 5 pub-
licly available genomes using a BLAST score ratio 
algorithm [7]. 
Finally, Fischer et al. in 2010 took the identification 
of an H. pylori core genome one step further by ap-
plying both homology via BLAST and synteny, 
conserved gene order, to find ~1200 core sequences 
in 7 strains [16].  
Had the Gressmann et al. study not utilized a 
„synthetic‟ genome sequence, it would have pro-
vided for an excellent reference to which our dataset 
could have been compared, as their 56-strain sample 
represented a collection of 800 strains. Instead, we 
compared our core genome with McClain et al., 
which utilized 5 strains, all of which were analyzed 
in the present study, and similarly employed 26695 
as the reference genome. Furthermore, McClain et 
al. used BLAST in the statistical analysis, therefore 
permitting a meaningful and efficient comparison of 
the resulting datasets.  We found that 672/676 
(99%) ORFs in the core genome of the present 
study are found in the McClain et al. dataset. Inter-
estingly, we found that the four ORFs not identified 
by McClain et al. (26695 Accession NP_206841.1, 
NP_207995.1, NP_208072.1 and NP_208329.1) are 
92%-98% identical in the seven genomes analyzed 
here. It is unclear how these highly similar genes 
were overlooked.  
We attribute the large difference in size between the 
two datasets to factors involving the phased method 
of triaging unrelated sequences in the present study 
by amino acid relatedness first and then sequence 
similarity, as well as the effect of the geographical 
distribution of strains upon composition of the core 
genome. First, a limited analysis of the ORFs      
present in McClain et al. but not identified in this 
study showed that the amino acid relatedness screen 
triaged genes that differed significantly in sequence 
at the N- or C-terminus across genomes as a result 
of gene “truncations.” The differences accounted for 
sufficiently lowered amino acid relatedness over 
entire ORF sequences thereby raising SΔn scores 
over the cut-off. Thus, the first screen for ORF simi-
larity accounts for discarded sequences. Further-
more, our higher stringency requirement of >80% 
sequence identity in comparison with the BLAST 
score ratio of 0.4 employed by McClain et al., 
which represents a 30% sequence identity over 30% 
of sequence length, may have resulted in a greater 
number of sequences of core sequences to be in-
cluded in McClain et al. 
Additionally, geographical diversity among H. py-
lori strains may account for differences in the core 
genome datasets. Of the 1237 core genes identified 
in McClain et al., a subset of alleles was highly di-
vergent in the East Asian strain 98-10, encoding 
proteins that exhibited <90% amino acid sequence 
identity when compared to the corresponding pro-
tein in the 4 other strains analyzed; similar results 
were shown for the J99 strain which is most closely 
related to H. pylori isolates from West Africa. Thus, 
the McClain et al. dataset contained some highly 
divergent strain sequences with <90% sequence 
identity present in 98-10 and J99 strains, many of 
which would not have met the 80% cut-off in this 
study.  Moreover, our core dataset included se-
quences present in two strains of East Asian origin, 
98-10 and Shi470, the latter of which is a Peruvian 
strain, but which is more closely related to strains 
from East Asia. The high sequence divergence in-
herent to East Asian H. pylori strains could also 
have accounted for the smaller size of our core. 
Therefore, choice of strain and variation in se-
quence composition of strains selected for analysis 
affect the resulting size of core genome determined.  
 
Conserved 9-mer search 
9-mer sequences parsed out of the 676 core genome 
ORFs from the reference strain were searched for 
identically parsed 9-mers in the matching ORFs of 
query strains using the Conservatrix algorithm [17]. 
A 9-amino acid frame was used because it is the 
length of a peptide that fits into the HLA binding 
pocket. We found that out of the 1,241,153 9-mers 
parsed, 106,791 were identical amongst all seven 
genomes (Figure 2). We next examined the poten-
tial immunogenicity of these sequences using com-
putational methods depicted below. 
Figure 3 - H. pylori Core and Dispensable Genomes. 
Using H. pylori 26695 as a reference strain, the genomes of seven H. pylori 
strains were compared to discover a core set of ORFs for identification of 
vaccine immunogen candidates. This Venn diagram illustrates the number 
of ORFs in 26695 that are common to at least one other genome. ORFs 
common to all genomes compose an H. pylori core genome. 
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Epitope mapping 
Each of the 106,791 9-mers was scored for pre-
dicted binding affinity to a panel of 8 Class II HLA 
alleles using EpiMatrix, a matrix-based algorithm 
for mapping T-cell epitopes [18]. The algorithm 
was previously benchmarked against similar predic-
tion tools, including SMM-align, IEDB ARB, TEPI-
TOPE, MHCPRED among others, and shown to 
have a sensitivity rating, on average, for HLA Class 
II predictions of 77%, which is 5-17% greater than 
the others [19]. A total of 23,654 9-mer sequences 
had a z-score ≥1.64 for at least one Class II HLA 
allele (Figure 2). The sequences were ranked ac-
cording to the cumulative EpiMatrix score for all 8 
alleles to serve as a starting point for the construc-
tion of immunogenic consensus sequences. 
 
ICS construction 
Immunogenic consensus sequences were built by 
EpiAssembler, an algorithm that maximizes epitope 
density in a 20-25 amino acid stretch by assembling 
potentially immunogenic 9-mers identical to their 
placement in the native protein antigen [17]. The 
basis for this approach to vaccine immunogen de-
sign lies in the observation that immunogenicity is 
not randomly distributed throughout protein se-
quences but instead tends to cluster. Designing vac-
cine immunogens with increased epitope density 
improves the possibility for epitope presentation to 
T cells in the context of more than one HLA allele, 
thereby broadly covering an HLA diverse human 
population. EpiAssembler produced 1,807 ICS from 
the input sequences (Figure 2). The number of 9-
mer epitopes per ICS ranges from 4 to 11 with an 
average of 6.52 ± 1.23 (standard deviation). Be-
cause a single 9-mer epitope may bind more than 
one HLA allele, the number of predicted 9-mer epi-
topes across all 8 alleles was counted for each ICS. 
The number of hits per ICS ranges from 12 to 55 
with an average of 22.72 ± 6.49 (standard devia-
tion).  
 
Human cross-reactivity 
To avoid potential cross-reactivity with human se-
quences that may stimulate autoimmunity, epitopes 
that are homologous to components of the human 
genome were triaged while the remaining “foreign” 
epitopes (i.e. those lacking homology to human) 
were considered safe to include in vaccine formula-
tions. As a standard practice, any peptide that shares 
greater than 70% identity (or more than 7 identities 
per 9-mer frame) with sequences contained in the 
human proteome is eliminated from consideration. 
Among the 1,807 ICS, two were significantly ho-
mologous to human sequences and were therefore 
excluded from the set of potential vaccine immuno-
gens (Figure 2).  
Cross reactivity with human gut microbiota is an 
equally important consideration in selection of vac-
cine immunogens. A major goal of the Human Mi-
crobiome Project, an NIH roadmap initiative, is to 
sequence and publish the genomes of gut microbi-
ota. A BlastiMer analysis of the ICS sequences will 
be performed as these genome sequences become 
available. 
 
ICS selection 
ICS to be studied by experimental methods in order 
to validate computational predictions must have 
Figure 4 - COGs Classification Analysis. 
COGs analysis of the H. pylori 26695 genome, core genome subset, and ICS. Metabolic (36% Whole Genome (WG), 26% Core Genome (CG), 53% ICS). 
Cellular processes/signalling (20% WG, 21% CG, 17% ICS). Poorly characterized (12% WG, 12% CG, 9% ICS).  Information storage/processing (17% WG, 
15% CG, 10% ICS). Not in COGs (15% WG, 25% CG, 11% ICS).  
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physicochemical properties compatible with peptide 
synthesis and experimental conditions. Hydropho-
bicity is an important parameter to consider because 
hydrophobic peptides can be difficult to synthesize, 
purify and solvate in aqueous buffers. To address 
this concern, the average hydropathy score for all 
the amino acids in an ICS was calculated [20]. Of 
the 1,805 ICS, 28 had hydrophobicity scores >2 and 
were removed from further consideration. 
The remaining 1,777 ICS clusters were then ranked 
according to EpiMatrix ICS score, as calculated by 
summing the individual EpiMatrix scores for all 9-
mer epitopes scoring at least 1.64 for all 8 Class II 
HLA alleles. The top 120 clusters that were selected 
are comprised of sequences that originate from 101 
distinct ORFs with EpiMatrix scores ranging from 
51.59 to 104.18. With regard to immunogenic se-
quences previously identified, none of the ICS clus-
ters contain T-cell epitopes deposited in the Immune 
Epitope Database (http://www.immuneepitope.org/) 
and are therefore novel potential vaccine candidates.  
According to the clusters of orthologous groups 
(COGs) classification system, these ORFs consist of 
53% metabolic, 17% cell process and signaling, 
10% information storage and processing and 9% 
poorly characterized proteins (Figure 4) [21; http://
www.ncbi.nlm.nih.gov/sutils/coxik.cgi?gi=128]. In 
comparison with the distribution of ORFs for the 
entire 26695 genome, metabolic proteins are strik-
ingly over-represented in the ICS dataset, while the 
other protein groups are closer in proportion. It is 
possible that H. pylori metabolic proteins, as a 
group, are more divergent than the others. Indeed, 
metabolic proteins of Salmonella enterica subspe-
cies typhi and typhimurium have the greatest ten-
dency for divergence, while their information proc-
essing proteins are least likely to evolve [22]. Thus, 
greater sampling of sequence space during evolu-
tion to acquire new metabolic functions may come 
at the detriment of host immune evasion with an 
increase in potential T cell immunogenicity. We 
further investigated whether the greater frequency 
of epitopes originating in metabolic proteins was 
pre-determined by core genome ORF selection and 
found that metabolic proteins are under-represented 
in the core genome in comparison with the whole 
genome (Figure 4). Thus, over-representation of 
metabolic proteins among ICS clusters suggests that 
they may be a special class of potential vaccine im-
munogens.  
Because machine generated ICS are not optimally 
designed for peptide synthesis, the top 120 se-
quences were reviewed and “hand-edited” before 
attempting synthesis. This involved (i) dividing ICS 
where two distinct regions of immunogenic density 
were observed and (ii) trimming sequences to center 
around high scoring 9-mers for >3 HLA alleles. 
Hand-edited sequences that raised hydrophobicity 
scores over the cut-off described above were tri-
aged. In total, 109 ICS with EpiMatrix scores     
ranging from 12.29 to 88.93 were submitted for 
peptide synthesis and 78 were successfully pro-
duced. 
 
HLA binding 
ICS peptides were assayed in vitro for their capacity 
to bind multiple HLA types, including DRB1*0101, 
DRB1*0301, DRB1*0401, DRB1*0701, 
DRB1*1101 and DRB1*1501. Of the 468 ICS pep-
tide-HLA binding interactions assayed, 54% dis-
played strong binding (estimated IC50<10 M), 24% 
showed moderate or weak binding (10 
M<estimated IC50<100 M) and 21% displayed no 
binding (estimated IC50>100 M) (Table 2). 
All peptides bound to at least one of the HLA al-
leles for which they were predicted to bind, 97% 
bound to two alleles, 87% bound to three, 79% 
bound to four, 65% bound to five and 44% bound to 
all. These data support the use of this approach for 
the high-volume genomic screening for vaccine 
candidates. Therefore, we will proceed to the next 
step in the genomes-to-vaccine development proc-
ess with these highly conserved, highly promiscu-
ous candidate epitopes. 
We analyzed the proportion of HLA binding pep-
tides that were correctly predicted by immunoinfor-
matic methods to assess the concordance of compu-
tational predictions and experimental results. We 
classified each binding reaction categorically as ei-
ther a true positive, false positive, or true negative 
with positive predictions defined as epitopes scoring 
≥1.64 on the EpiMatrix Z-scale and binding HLA at 
IC50<100µM. All but three ICS peptides were pre-
dicted to bind all HLA alleles assayed. As the three 
ICS below the EpiMatrix cut-off for a positive bind-
ing prediction failed to bind HLA in vitro, there 
were no false negative results in these assays. Over-
all, the proportion of true positive predictions is 
79% (Figure 5). With respect to each allele assayed, 
the values are 81% for DRB1*0101, 63% for 
DRB1*0301, 62% for DRB1*0401, 88% for 
DRB1*0701, 94% for DRB1*1101 and 87% for 
DRB1*1501. Categorical evaluations of each pep-
tide‟s EpiMatrix prediction association to in vitro 
HLA-binding were collected into a 2x2 contingency 
table. By chi-squared test, the association between 
immunoinformatic predictions (EpiMatrix Z-score 
≥1.64) and HLA-binding results (IC50<100µM) is 
highly significant (p = 0.0007).  
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Table 1  - Top 120 Immunogenic Consensus Sequences 
SEQUENCE refers to the amino acid sequence of the given ICS. SOURCE PROTEIN refers to the protein description from which each ICS is derived. 26695 
ACCESSION NUMBER refers to the GenBank accession number source of the initial 9-mer “seed” for each ICS. EPX CLUSTER SCORE refers to the 
overall sum of significant scores aggregated and normalized. 
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Table 1  - Top 120 Immunogenic Consensus Sequences (continued) 
SEQUENCE refers to the amino acid sequence of the given ICS. SOURCE PROTEIN refers to the protein description from which each ICS is derived. 26695 
ACCESSION NUMBER refers to the GenBank accession number source of the initial 9-mer “seed” for each ICS. EPX CLUSTER SCORE refers to the 
overall sum of significant scores aggregated and normalized. 
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Table 2  - Validation of HLA Binding Prediction in HLA Binding Assay 
PEPTIDE ID refers to a four-digit identifier for each ICS peptide. 26695 ACCESSION NUMBER refers to the GenBank accession number source of the 
initial 9-mer “seed” for each ICS peptide. SEQUENCE refers to the amino acid sequence of the given ICS peptide. DRB1 ALLELES refers to the alleles 
tested for ICS peptide binding; estimated binding affinities are IC50 <1 µM (dark gray), 1 µM < IC50 < 10 µM (medium gray), 10 µM < IC50 < 100 µM (light 
gray), IC50 >100 µM (white). 
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A number of possible explanations may account for 
the lack of accord between positive predictions and 
actual binding, including peptide folding, peptide 
aggregation under assay conditions, or the predic-
tive accuracy of immunoinformatic algorithms. In a 
large, retrospective comparison of the EpiMatrix 
with epitope mapping algorithms in the public     
domain, EpiMatrix was >75% accurate across all 
the HLA Class II alleles studied here, which is as 
accurate as or more accurate than other epitope pre-
diction tools [18]. Therefore, it is likely that a sig-
nificant part of the discrepancy between predictions 
and HLA binding is due to peptide design and 
physical properties. 
 
 
Conclusions  
 
Using a genomes-to-vaccine approach described 
here, we were able to systematically narrow down 
over 1.2 million 9-mer sequences from seven bacte-
rial genomes to an experimentally feasible number 
of potential vaccine candidates that demonstrate the 
capacity to bind HLA. In so doing, we derived a 
conservative estimate of the H. pylori core genome 
in comparison with previously reported core ge-
nomes. Furthermore, we observed that metabolic 
proteins might comprise a special group of H. pylori 
vaccine immunogens; the same may be the case in 
other microbial species but requires further investi-
gation.  
In future studies, we will further validate the ICS 
peptides by evaluating their antigenicity through 
activation of T cells cytokine production in periph-
eral blood and gastric biopsy specimens obtained 
from H. pylori-infected patients. In addition, ICS 
peptide immunogenicity will be evaluated in vivo 
using humanized mice that express HLA DR1, DR3 
and DR4. Broadly antigenic and immunogenic ICS 
will then be concatenated to generate a multi-
epitope sequence for production of DNA and pro-
tein vaccines that will be assessed for immuno-
genicity and protection against H. pylori infection. 
 
Methods 
Immunoinformatics 
Seven H. pylori genomes were downloaded from 
the National Center for Biotechnology Information 
(www.ncbi.nlm.nih.gov) in September 2009, includ-
ing Helicobacter pylori 26695 (Accession 
NC000915; 1576 ORFs), Helicobacter pylori J99 
(Accession NC000921; 1489 ORFs), Helicobacter 
pylori HPAG1 (Accession NC008086; 1536 ORFs), 
Helicobacter pylori G27 (Accession NC011333; 
1493 ORFs), Helicobacter pylori Shi470 
(Accession NC010698; 1569 ORFs), Helicobacter 
pylori B128 (Accession NZABSY00000000; 1731 
ORFs) and Helicobacter pylori 98-10 (Accession 
NZABSX00000000; 1527 ORFs). Sequences were 
downloaded in GenPept format, where the accession 
number and corresponding amino acid sequence 
were exported and then uploaded to an in-house 
database. Conservatrix was used to parse input se-
quences into 9-mer strings and to search the result-
ing dataset for matching segments. A frequency ta-
ble showing each unique segment in the dataset and 
the number of times that the sequence occurs was 
produced. The EpiMatrix algorithm was used to 
compare the amino acid sequence of each given 9-
mer peptide to the coefficients contained in the ma-
trix and produced a raw score. In order to compare 
potential epitopes across multiple HLA alleles, Epi-
Matrix raw scores were converted to a normalized 
“Z” scale. Peptides scoring ≥1.64 on the EpiMatrix 
“Z” scale (typically the top 5% of any given sam-
ple), are likely to be MHC ligands and are consid-
ered “hits”. Class II epitopes were identified for 8 
archetypal alleles that cover >90% of the human 
Figure 5  - Comparison of Computa-
tional Predictions and HLA Binding 
Assay Results. 
All ICS are predicted to bind at least one 
HLA allele tested in assay but not all are 
predicted to bind all six alleles. True posi-
tives represent sequences predicted to be 
HLA ligands (EpiMatrix Z-score ≥1.64) 
and bind in assay (IC50 <100 M). False 
positives are sequences predicted to bind 
but do not in assay. True negatives are 
sequences not predicted to bind and do not 
bind in assay. No sequences that bound 
HLA in assay were predicted not to bind, 
thus there are no false negatives. With 
respect to each individual HLA allele, true 
positive predictions are 81% for 
DRB1*0101, 63% for DRB1*0301, 62% 
for DRB1*0401, 88% for DRB1*0701, 
94% for DRB1*1101, and 87% for 
DRB1*1501. Overall, binding predictions 
were confirmed in 79% of cases. 
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populat ion  (DRB1*0101,  DRB1*0301, 
DRB1*0401, DRB1*0701, DRB1*0801, 
DRB1*1101, DRB1*1301 and DRB1*1501) [23].  
ICS construction begins with selecting a single 9-
mer sequence to “seed” growth. EpiAssembler 
searches for the highest-scoring segments that natu-
rally overlap either the N-terminal or C-terminal of 
the “seed” epitope. Each time an overlapping seg-
ment is identified, it is added to the seed sequence. 
The extended sequence then becomes the new 
“seed” sequence and the process is repeated until 
the resulting sequence is no greater than 25 amino 
acids long. The significant EpiMatrix scores con-
tained within these ICS clusters are then aggregated 
to create an EpiMatrix cluster immunogenicity 
score. The choice of seed sequence at the beginning 
of each individual ICS construction was the highest 
ranking EpiMatrix-predicted epitope remaining in 
the list generated by epitope mapping. The Blas-
tiMer algorithm, which automates the process of 
submitting sequences to the BLAST engine at NCBI 
(www.ncbi.nlm.nih.gov/blast) and records results in 
a database that can be browsed, exported, or ren-
dered in a report format, was used to search the non-
redundant human genome database. 
Peptide Synthesis 
Peptides were manufactured using 9-
fluoronylmethoxycarbonyl (Fmoc) chemistry by 
21st Century Biochemicals (Marlboro, MA). Pep-
tides were purified to >80% as ascertained by ana-
lytical reversed phase HPLC. Peptide mass was 
confirmed by tandem mass spectrometry. 
 
HLA Binding Assay 
Class II HLA binding assays were used to screen 
predicted epitope sequences for binding multiple 
HLA alleles. We employed a competition-based 
HLA binding assay initially described by Steere et 
al. [24]. In 96-well plates, non-biotinylated test pep-
tides at three concentrations (1, 10 and 100 μM) 
competed for binding to soluble Class II molecules 
(50 nM) against a biotinylated standard peptide at a 
fixed concentration (0.1 µM) at 37°C for 24 hours 
to reach equilibrium. Class II molecules were then 
captured on ELISA plates using pan anti-Class II 
antibodies (L243, anti-HLA-DR). Plates were 
washed and incubated with Europium-labeled strep-
tavidin for 1 hour at room temperature. Europium 
activation buffer was added to develop the plates for 
15-20 minutes at room temperature before they 
were read on a Time Resolved Fluorescence (TRF) 
plate reader. All assays were performed in triplicate. 
An IC50 value was estimated to classify peptides as 
very high affinity binders (< 1 μM), high affinity (1 
μM< x<10 μM), moderate affinity (10 μM< x<100 
μM) or low affinity (>100 μM). Peptides classified 
as very high, high or moderate affinity were consid-
ered binders; those in the low affinity category were 
considered non-binders. Binding assays were per-
formed for 6 alleles: DRB1*0101, DRB1*0301, 
DRB1*0401, DRB1*0701, DRB1*1101 and 
DRB1*1501, which provided a broad representation 
of class II HLA allele binding pockets [23]. 
 
COMPETING INTERESTS 
Two of the contributing authors, Anne S. De Groot and William D. 
Martin are senior officers and majority shareholders at EpiVax, Inc., a 
privately owned vaccine design company located in Providence, RI. 
Leonard Moise has options in EpiVax, Inc. These authors acknowledge 
that there is a potential conflict of interest related to their relationship 
with EpiVax and attest that the work contained in this research report is 
free of any bias that might be associated with the commercial goals of 
the company. 
 
AUTHORS’ CONTRIBUTIONS 
MA performed immunoinformatics analysis and wrote the manuscript.  
JF performed comparative genomics analysis, designed strategy for 
core genome dataset comparison, and wrote the manuscript. 
RT performed and analyzed HLA binding assays. 
FT analyzed informatics and binding assay data and wrote the manu-
script. 
KDS performed genomics analyses. 
SZ analyzed informatics data. 
WM supervised and performed immunoinformatics analysis.  
ASDG supervised and performed immunoinformatics analysis. 
SFM assisted in study design and analyzed informatics data. 
LM supervised and designed the study, analyzed data and wrote the 
manuscript. 
 
  
ACKNOWLEDGEMENTS 
The authors wish to acknowledge the efforts of Lauren Levitz, who 
helped conduct the HLA-binding experiments. This study was sup-
ported by NIH 1U19AI082642. 
REFERENCES 
1. Aebischer T, Schmitt A, Walduck AK, Meyer TF: Helico-
bacter pylori vaccine development: facing the challenge. Int 
J Med Microbiol 2005, 295:343-353 
2. Wilson KT, Crabtree JE: Immunology of Helicobacter pylori: 
insights into the failure of the immune response and per-
spectives on vaccine studies. Gastroenterology 2007, 133:288
-308 
3. Moise L, McMurry JA, Pappo J, Lee DS, Moss SF, Martin 
WD, De Groot AS: Identification of genome-derived vaccine 
candidates conserved between human and mouse-adapted 
strains of H. pylori. Hum Vaccines 2008, 4:219-223  
4. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers 
AB, Martin W, De Groot AS. HelicoVax: Epitope-based 
therapeutic Helicobacter pylori vaccination in a mouse 
model. Vaccine 2011, 29:2085-91 
5. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, 
Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty 
BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson 
S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, 
McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey 
EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley 
JM, Cotton MD, Weidman, JM, Fujii C, Bowman C, Watthey 
L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, 
Fraser CM, Venter JC: The complete genome sequence of 
the gastric pathogen Helicobacter pylori. Nature 1997, 
388:539-547 
6. Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, 
Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, 
Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, 
Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis 
GF, Trust TJ: Genomic-sequence comparison of two unre-
lated isolates of the human gastric pathogen Helicobacter 
pylori. Nature 1999, 397:176-80 
 Ardito et al. Immunome Research 2011, 7:2:1                
http://www.immunome-research.net/          
         Page 12 of 12 
7. McClain MS, Shaffer CL, Israel DA, Peek RM Jr, Cover TL: 
Genome sequence analysis of Helicobacter pylori strains 
associated with gastric ulceration and gastric cancer. BMC 
Genomics 2009, 10:3 
8. Oh JD, Kling-Bäckhed H, Giannakis M, Xu J, Fulton RS, 
Fulton LA, Cordum HS, Wang C, Elliott G, Edwards J, Mardis 
ER, Engstrand LG, Gordon JI: The complete genome se-
quence of a chronic atrophic gastritis Helicobacter pylori 
strain: evolution during disease progression. Proc Natl 
Acad Sci U S A 2006, 103:9999-10004 
9. Kersulyte D, Kalia A, Gilman RH, Mendez M, Herrera P, 
Cabrera L, Velapatiño B, Balqui J, Paredes Puente de la Vega 
F, Rodriguez Ulloa CA, Cok J, Hooper CC, Dailide G, Tamma 
S, Berg DE: Helicobacter pylori from Peruvian amerindi-
ans: traces of human migrations in strains from remote 
Amazon, and genome sequence of an Amerind strain. PLoS 
One 2010, 5:e15076 
10. Baltrus DA, Amieva MR, Covacci A, Lowe TM, Merrell DS, 
Ottemann KM, Stein M, Salama NR, Guillemin K: The com-
plete genome sequence of Helicobacter pylori strain G27. J 
Bacteriol 2009, 191:447-8 
11. Cornish-Bowden A: Relating Proteins by Amino Acid Com-
position. Methods Enzymol 1983, 91:60-75 
12. Gotoh, O: An improved algorithm for matching biological 
sequences. J Mol Biol 1982, 162:705-708 
13. Henikoff S, Henikoff JG: Amino acid substitution matrices 
from protein blocks. Proc Natl Acad Sci U S A 1992, 
89:10915-10919 
14. Salama N, Guillemin K, McDaniel TK, Sherlock G, Tompkins 
L, Falkow S: A whole-genome microarray reveals genetic 
diversity among Helicobacter pylori strains. Proc Natl Acad 
Sci USA 2000, 97:14668-14673 
15. Gressmann H, Linz B, Ghai R, Pleissner KP, Schlapbach R, 
Yamaoka Y, Kraft C, Suerbaum S, Meyer TF, Achtman M: 
Gain and Loss of Multiple Genes During the Evolution of 
Helicobacter pylori. PLoS Genet 2005, 1:e43 
16. Fischer W, Windhager L, Rohrer S, Zeiller M, Karnholz A, 
Hoffmann R, Zimmer R, Haas R:  Strain-specific genes of 
Helicobacter pylori: genome evolution driven by a novel 
type IV secretion system and genomic island transfer. Nu-
cleic Acids Res 2010, 38:6089-6101 
17. De Groot AS, Bishop EA, Khan B, Lally M, Marcon L, Franco 
J, Mayer KH, Carpenter CC, Martin W: Engineering immu-
nogenic consensus T helper epitopes for a cross-clade HIV 
vaccine. Methods 2004, 34:476-487. 
18. De Groot AS, Jesdale BM, Szu E, Schafer JR, Chicz RM, 
Deocampo G: An interactive Web site providing major 
histocompatibility ligand predictions: application to HIV 
research. AIDS Res Hum Retroviruses 1997, 13:529-531 
19. De Groot AS, Martin W: Reducing risk, improving out-
comes: bioengineering less immunogenic protein therapeu-
tics. Clin Immunol 2009, 131:189-201 
20. Kyte J, Doolittle R: A simple method for displaying the hydro-
pathic character of a protein. J Mol Biol 1982, 157:105-132 
21. Tatusov RL, Koonin EV, Lipman DJ: A genomic perspective 
on protein families. Science 1997, 278:631-637 
22. Bhaduri A, Kalaimathy S, Sowdhamini R: Conservation and 
divergence among Salmonella enterica subspecies. Infect 
Disord Drug Targets 2009, 9:248-56 
23. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, 
Hoffman S, Kubo RT, Chestnut RW, Grey HM, Sette A: Sev-
eral common HLA-DR types share largely overlapping 
peptide binding repertoires. J Immunol 1998, 160:3363-3373 
24. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom 
GT, Baxter-Lowe LA: Antibiotic-refractory Lyme arthritis 
is associated with HLA-DR molecules that bind a Borrelia 
burgdorferi peptide. J Exp Med 2006, 203:961-971 
25. McMurry JA, Moise L, Gregory SH, De Groot AS: Tularemia 
vaccines - an overview. Med Health RI 2007, 90:311-4 
